Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1844117
23 February 2024 03:04PM

Contract for the sale of the MEDICLIN Herzzentrum Coswig has been signed


EQS-News: MediClin AG / Key word(s): Disposal/Miscellaneous
MEDICLIN: Contract for the sale of the MEDICLIN Herzzentrum Coswig has been signed

23.02.2024 / 15:04 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, February 23, 2024

MEDICLIN: Contract for the sale of the MEDICLIN Herzzentrum Coswig has been signed

The contract for the sale of the MEDICLIN Herzzentrum Coswig has been signed. The new owner is Johannesstift Diakonie, a diaconal healthcare and social organisation in Berlin and north-eastern Germany, which operates 60 facilities in Berlin, Brandenburg, Saxony-Anhalt, Mecklenburg-Western Pomerania, Thuringia and Lower Saxony.  

"We believe that the sold clinic and our employees - embedded in a strong regional network - are in really good hands. The clinic thus has the best prospects of mastering the upcoming challenges that we will all face as a result of the hospital reform," explains Dr Joachim Ramming, CEO of MEDICLIN.

The MEDICLIN Management Board has already personally informed the employees of the clinic about the new owner of the clinic. "The dialogue with colleagues on site was very good and the news about the upcoming change of ownership was well received," says Tino Fritz, CFO at MEDICLIN. "The most important thing is that the jobs are secure and that the clinic can continue to develop excellently in line with its medical potential."

Medical supply security for the population

This is also the view of the Medical Director of the MEDICLIN Herzzentrum Coswig, PD Dr Harald Hausmann: "Over the past 25 years, our facility has developed into the leading clinic for the surgical and invasive treatment of heart disease in Saxony-Anhalt. Many patients now also come from Brandenburg, Saxony and Berlin for treatment. They are in good hands at our clinic, as our highly motivated doctors and nursing and therapy staff come together here every day to treat patients with high quality and a great deal of empathy." He adds: "The change of ownership to Johannesstift Diakonie means that the clinic will be integrated into a hospital group that is already well networked and positioned in our region and can create many synergies with us. This means medical supply security for the population and job security for the employees. We are extremely positive about the future of cardiac medicine in our region!"

Around 340 people are currently employed at the MEDICLIN Herzzentrum Coswig. It is planned that the employment relationships will be transferred unchanged to the new owner. The transfer of operations is scheduled to take place as soon as possible.

In line with its own corporate strategy, the healthcare company MEDICLIN will focus even more strongly on medical rehabilitation in future. "However, this does not mean that we will exclusively operate rehabilitation facilities in the future. Nevertheless, it may make sense to place individual facilities in good hands. Particularly in view of the expected effects of the hospital reform, such considerations are even necessary," emphasises Ramming.

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group

 


23.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1844117

 
End of News EQS News Service

1844117  23.02.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1844117&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.